AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is expanding its push into Alzheimer’s with a new study titled “A...

AbbVie Steps Deeper Into Alzheimer’s: What the ABBV-1758 Trial Means for Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Liquidia Technologies (LQDA), AbbVie (ABBV) and Esta...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s phase 3 study, BOTOX® (onabotulinumtoxinA) for the Reduction of Masset...

AbbVie’s BOTOX Jawline Trial Wraps Up: What the Masseter Study Means for ABBV Investors

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s latest update covers a completed early study testing venetoclax with a...

AbbVie’s Venetoclax Combo in High-Risk MDS: What a Fresh Trial Update Signals for Investors

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has launched a Phase 2 dose‑finding study titled “A Phase 2 Dose-...

AbbVie Targets Obesity Market With New Phase 2 ABBV-295 Trial

Berenberg Bank analyst Luisa Hector maintained a Buy rating on AbbVie yesterday and set a price target of $275.00. The company’s shares closed yest...

AbbVie (ABBV) Gets a Buy from Berenberg Bank

AbbVie ( ($ABBV) ) has issued an update. On August 4, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to issue ...

AbbVie prices $9.9B senior notes to fund acquisition

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is running a late-stage study called “A Phase 3 Randomized, Open Label, ...

AbbVie’s ABBV-706 Lung Cancer Trial: A New Late-Stage Bet in Small Cell Oncology

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viking Therapeutics (VKTX), AbbVie (ABBV) and Cenc...

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), AbbVie (ABBV) and Cencora (COR)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a new observational study called “A Concordance Study ...

AbbVie Targets Ovarian Cancer Biomarkers With New FRa Concordance Study

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a global Phase 2/3 study called “A Randomized Phase 2/...

AbbVie’s New AML Combo Trial Aims to Boost Its Oncology Pipeline

In a report released today, Emily Field from Barclays maintained a Buy rating on AbbVie, with a price target of $300.00. According to TipRanks, Fie...

Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s first-in-human Phase 1 trial, officially titled “A First-In-Human Stud...

AbbVie’s ABBV-722 Phase 1 Milestone: What Early Safety Data Means for Investors

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has completed a real-world study called “Real-world Effectiveness and Tr...

AbbVie Wraps Up Real-World RINVOQ Study in Psoriatic Arthritis: What Investors Should Watch

Stocks ended the week mixed as strength in blue-chip shares offset losses in technology and semiconductor stocks. The Dow Jones Industrial Average ...

The Week That Was, The Week Ahead: Macro and Markets, July 26

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has launched a new Phase 1 study called “A Phase 1, Randomized, Double-B...

AbbVie’s ABBV-313 Phase 1 Trial: What Early Safety Work Means for Investors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Integer Holdings (ITGR), Thermo Fisher (TMO) and A...

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s latest Phase 1 update centers on how its drug ABBV-8736 moves through ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$249.46	-0.54%	4.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$249.46	-0.5%	4.19M
3
4
5
6

ABBV

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel